Core Insights - Genentech, a member of the Roche Group, announced positive Phase III results from the lidERA Breast Cancer study for giredestrant as an adjuvant endocrine treatment for ER-positive, HER2-negative early-stage breast cancer [1] Group 1 - The study met its primary endpoint at a pre-planned interim analysis [1] - The results showed a statistically significant outcome [1]